BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32584703)

  • 1. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
    Gong Z; Wang Y
    JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
    Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
    Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
    J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.
    Abu-Sbeih H; Ali FS; Wang Y
    Curr Opin Gastroenterol; 2020 Jan; 36(1):25-32. PubMed ID: 31609734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
    Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
    J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
    Ma W; Gong Z; Abu-Sbeih H; Peng Y; Peng F; Zou F; Charabaty A; Okhuysen PC; McQuade JL; Altan M; Zhang HC; Thomas AS; Wang Y
    Am J Clin Oncol; 2021 Aug; 44(8):402-408. PubMed ID: 34107499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.
    Zou F; Wang X; Glitza Oliva IC; McQuade JL; Wang J; Zhang HC; Thompson JA; Thomas AS; Wang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways.
    Sleiman J; Brand RM; Pai R; Brand RE; Rhee J; Schwartz M; Davar D
    Clin J Gastroenterol; 2023 Oct; 16(5):680-684. PubMed ID: 37452993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
    Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
    Zou F; Faleck D; Thomas A; Harris J; Satish D; Wang X; Charabaty A; Ernstoff MS; Glitza Oliva IC; Hanauer S; McQuade J; Obeid M; Shah A; Richards DM; Sharon E; Wolchok J; Thompson J; Wang Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34789551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal Tract Adverse Events.
    Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2020; 1244():247-253. PubMed ID: 32301019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
    Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
    J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors-Induced Colitis.
    Tian Y; Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
    Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
    Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
    Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
    Liu C; Shatila M; Mathew A; Machado AP; Thomas A; Zhang HC; Thomas AS; Faleck D; Funchain P; Philpott J; Grivas P; Obeid M; Carbonnel F; Wang Y
    J Cancer; 2023; 14(10):1913-1919. PubMed ID: 37476185
    [No Abstract]   [Full Text] [Related]  

  • 18. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.
    Saji A; Chopra M; Jacob J; Altan M; Alhalabi O; Shah AY; Qiao W; Wang Y; Thomas A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5841-5852. PubMed ID: 36585982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
    Bonanno L; Lorenzi M; Massa D; De Nuzzo M; Angerilli V; Zingone F; Barberio B; Russi A; Girardi F; Ferro A; Dal Maso A; Frega S; Pasello G; Dei Tos AP; Coppola M; Fassan M; Savarino EV; Guarneri V
    Oncologist; 2024 Jan; 29(1):e118-e130. PubMed ID: 37603442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease.
    Abu-Sbeih H; Wang Y
    Inflamm Bowel Dis; 2020 Apr; 26(5):662-668. PubMed ID: 31560045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.